Ads
related to: medications for obstructive hypertrophic cardiomyopathy
Search results
Results from the WOW.Com Content Network
Mavacamten, sold under the brand name Camzyos, is a medication used to treat obstructive hypertrophic cardiomyopathy. [8] [9] Mavacamten is a small-molecule allosteric [10] and cardiac myosin inhibitor. [8] It was developed by MyoKardia, a subsidiary of Bristol Myers Squibb. [11]
Aficamten (CK-274) is a cardiac myosin inhibitor [1] developed by Cytokinetics for the treatment of obstructive hypertrophic cardiomyopathy. [ 2 ] [ 3 ] [ 4 ] References
Hypertrophic cardiomyopathy (HCM, or HOCM when obstructive) is a condition in which muscle tissues of the heart become thickened without an obvious cause. [8] The parts of the heart most commonly affected are the interventricular septum and the ventricles . [ 10 ]
A new medication for obstructive HCM patients with more severe/progressed disease, mavacamten (which acts to reduce the contractility of the hypertrophied cardiac muscle), was approved by the Food ...
MYK-224 is a small-molecule cardiac myosin inhibitor developed by Bristol Myers Squibb for hypertrophic cardiomyopathy. [1] [2] [3] References
At the time of diagnosis, most people with hypertrophic cardiomyopathy will have no symptoms and no evidence of an obstruction. Apart from follow-up monitoring, most won’t require treatment.
Hypertrophic cardiomyopathy. Hypertrophic cardiomyopathy develops when the walls of your left ventricle become thicker than normal. It’s the most common cardiomyopathy caused by inherited genes.
It is estimated that there are 600,000 individuals in the United States with hypertrophic cardiomyopathy. The most common variant of HCM presents with left ventricular (LV) intracavitary obstruction due to systolic anterior motion of the mitral valve, and mitral-septal contact, diagnosed readily with echocardiography.
Ads
related to: medications for obstructive hypertrophic cardiomyopathy